<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130777</url>
  </required_header>
  <id_info>
    <org_study_id>2016-04</org_study_id>
    <nct_id>NCT03130777</nct_id>
  </id_info>
  <brief_title>Multicenter Trial of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent</brief_title>
  <acronym>ALTERRA</acronym>
  <official_title>Multicenter Early Feasibility Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 Transcather Heart Valve With the Alterra Adaptive Prestent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and functionality of the Edwards Alterra Adaptive Prestent in
      conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in patients with
      a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated
      for treatment of pulmonary regurgitation (PR).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, prospective, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device Success</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as a non-hierarchical composite of:
Single Alterra Adaptive Prestent deployed into the desired location
Single THV implanted in the desired location within the Alterra Adaptive Prestent (staged procedures allowed)
Right ventricle to pulmonary artery (RV-PA) peak-to-peak gradient &lt; 35 mmHg post-THV implantation
Less than moderate total PR by discharge TTE (or earliest evaluable TTE)
Free of Alterra explant at 24 hours post-implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Free from THV dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>THV dysfunction is defined as a non-hierarchical composite of RVOT/PV reintervention
Moderate or greater total PR via Transthoracic Echocardiography (TTE)
Mean RVOT/PV gradient ≥35 mmHg via TTE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Transpulmonary Valve Replacement</condition>
  <condition>Pulmonary Stenosis</condition>
  <condition>TPVR</condition>
  <condition>Tetralogy of Fallot</condition>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>SAPIEN 3 THV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To demonstrate the safety and functionality of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Alterra Adaptive Prestent with SAPIEN 3 THV</intervention_name>
    <description>The Edwards Alterra Adaptive Prestent is designed to provide a simple and safe way to reduce the diameter of these large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.</description>
    <arm_group_label>SAPIEN 3 THV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient/patient's legally authorized representative has been informed of the
             nature of the study, agrees to its provisions and has provided written informed
             consent.

          2. Pediatric or adult patent whose weight is ≥ 20 kg (44 lbs).

          3. The patient has a dysfunctional RVOT/PV.

          4. RVOT/PV proximal and distal landing zone diameter ≥ 27 mm and ≤ 38 mm and/or minimum
             of 35 mm from contractile tissue to lowest pulmonary artery takeoff immediately prior
             to Alterra Prestent insertion.

        Exclusion Criteria:

          1. Active infection requiring current antibiotic therapy (if temporary illness, patient
             may be a candidate 2 weeks after discontinuation of antibiotics).

          2. History of or active endocarditis (active treatment with antibiotics) within the past
             180 days.

          3. Leukopenia (WBC &lt; 2000 cells/μL), anemia (Hgb &lt; 7 g/dL), thrombocytopenia (platelets &lt;
             50,000 cells/μL) or any known blood clotting disorder.

          4. Inappropriate anatomy for introduction and delivery of the Alterra Adaptive Prestent
             or the SAPIEN 3 THV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Zahn, MD, FACC, FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erika Tequia</last_name>
    <phone>949-756-4652</phone>
    <email>Erika_Tequia@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tenley Koepnick</last_name>
    <email>Tenley_Koepnick@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

